Market Overview

Oppenheimer on Serepta: Farkas Departure From FDA Is A Positive Signal For Eteplirsen Approval

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for SRPT

DateFirmActionFromTo
Apr 2017SunTrust Robinson HumphreyUpgradesHoldBuy
Mar 2017NomuraInitiates Coverage OnBuy
Mar 2017Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (SRPT)